A 1-Year Study to Compare the Efficacy and Safety of Once-Daily Travoprost 0.004%/Timolol 0.5% to Once-Daily Latanoprost 0.005%/Timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension

Abstract

Travoprost 0.004%/timolol 0.5% ophthalmic solution produced mean IOP levels that are statistically noninferior to latanoprost 0.005%/timolol 0.5% ophthalmic solution. Furthermore, at 9:00 AM, 24 hours after dosing, IOP was statistically lower for travoprost 0.004%/timolol 0.5% pooled across all visits. Travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution is an effective treatment for reducing IOP and it is safe and well-tolerated in patients with OAG or OH.

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

“…33 We believe that such an evaluation meets our inclusion criteria of a prostaglandin versus an inert control as the prostaglandin effect here is the same relative effect as if it were prostaglandin versus nothing. We have conducted a sensitivity analysis to examine if our findings would differ on the primary outcome of IOP-lowering effects.…”

“…We found several instances where the primary outcomes were not significantly different, but the authors reported them as clinically important in their conclusions. 33 Further, on average, the trials included in our analysis were small. There is a clear need for minimum sample sizes in equivalence trials of PGAs to avoid wasted resources and potentially spurious outcomes.…”

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

“…Prostaglandin analogs for ocular hypertension and glaucoma FCLT (16.7 to 17.7 mmHg), 100 supported by a retrospective, cross-sectional study. 210 However, ocular hyperemia rates were higher with FCTT (15%) compared with FCLT (2.5%).…”

“…210 However, ocular hyperemia rates were higher with FCTT (15%) compared with FCLT (2.5%). 100 Compared with FCDT, mean pooled diurnal IOP was significantly lower with FCTT (16.5 ± 0.23 mmHg vs 17.3 ± 0.23 mmHg; P = 0.011) in a randomized-control, parallel, double-masked trial (n = 319). 209 FCTT produced mean IOP reductions of 35.3% to 38.5%, FCDT reduced IOP 32.5% to 34.5%.…”

“…88 An industry-sponsored meta-analysis 90 of travoprost vs latanoprost (15 trials, n = 1098), 57,68,85,93,95,96,[98][99][100] travoprost vs bimatoprost (8 trials, n = 714), 57,85,87,93,95,96,101,102 and latanoprost vs bimatoprost (8 trials, n = 943) 57,64,85,86,93,95,96,103 found similar efficacy among the three PGAs. Studies comparing the PGA to other non-PGA glaucoma treatments, nonrandomized, dose-finding or cross-over trials, and short-term evaluations (less than 3 months) were excluded, although a trial evaluating timolol plus travoprost versus timolol alone, 100 was included indicating that the PGA effect has the same relative effect as if it were compared with no treatment. Another industry-sponsored meta-analysis by Denis et al 91 of 9 randomized trials 63,68,78,85,86,92,93,101,104 (n = 1318) found adjusted IOP was similar for bimatoprost and travoprost, but more favorable than latanoprost treated subjects.…”